Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip R Greipp

Showing results (51-60 of 113) with videos related to

Pageof 12
Sort By:
Blood|December 13, 2005
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification systemDavid Dingli, Grzegorz S Nowakowski, Angela Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myelomaS Vincent Rajkumar, Suzanne Hayman, Morie A Gertz, et al.
Blood|December 8, 2009
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcomeJames J Driscoll, Dheeraj Pelluru, Konstantinos Lefkimmiatis, et al.
Blood|June 16, 2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaSumit Madan, Martha Q Lacy, Angela Dispenzieri, et al.
Blood|October 24, 2002
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosisAnimesh Pardanani, Thomas E Witzig, Georgene Schroeder, et al.
Haematologica|December 7, 2005
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trialDavid Dingli, S Vincent Rajkumar, Grzegorz S Nowakowski, et al.
Seminars in Oncology|April 30, 2003
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRoger G Owen, Steven P Treon, Ayad Al-Katib, et al.
Blood|February 11, 2003
Clinical and biologic implications of recurrent genomic aberrations in myelomaRafael Fonseca, Emily Blood, Montserrat Rue, et al.
Blood|September 28, 2002
Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletionsRoelandt F J Schop, W Michael Kuehl, Scott A Van Wier, et al.
Cancer Genetics and Cytogenetics|August 30, 2006
6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significanceRoelandt F J Schop, Scott A Van Wier, Ruifang Xu, et al.
Pageof 12

Showing results (51-60 of 113) with videos related to

Sort By:
Pageof 12
Blood|December 13, 2005
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification systemDavid Dingli, Grzegorz S Nowakowski, Angela Dispenzieri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myelomaS Vincent Rajkumar, Suzanne Hayman, Morie A Gertz, et al.
Blood|December 8, 2009
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcomeJames J Driscoll, Dheeraj Pelluru, Konstantinos Lefkimmiatis, et al.
Blood|June 16, 2011
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myelomaSumit Madan, Martha Q Lacy, Angela Dispenzieri, et al.
Blood|October 24, 2002
Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosisAnimesh Pardanani, Thomas E Witzig, Georgene Schroeder, et al.
Haematologica|December 7, 2005
Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trialDavid Dingli, S Vincent Rajkumar, Grzegorz S Nowakowski, et al.
Seminars in Oncology|April 30, 2003
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaRoger G Owen, Steven P Treon, Ayad Al-Katib, et al.
Blood|February 11, 2003
Clinical and biologic implications of recurrent genomic aberrations in myelomaRafael Fonseca, Emily Blood, Montserrat Rue, et al.
Blood|September 28, 2002
Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletionsRoelandt F J Schop, W Michael Kuehl, Scott A Van Wier, et al.
Cancer Genetics and Cytogenetics|August 30, 2006
6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significanceRoelandt F J Schop, Scott A Van Wier, Ruifang Xu, et al.
Pageof 12